Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Harvard Business School
McKesson
Mallinckrodt
Baxter

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,846,961

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which drugs does patent 7,846,961 protect, and when does it expire?

Patent 7,846,961 protects PRESTALIA and is included in one NDA.

This patent has thirty patent family members in twenty-seven countries.

Summary for Patent: 7,846,961
Title:.alpha. crystalline form of the arginine salt of perindopril, a process for its preparation and pharmaceutical compositions containing it
Abstract: .alpha.-crystalline form of the compound of formula (I): ##STR00001## characterized by its powder X-ray diffraction diagram. Medicinal products containing the same which are useful as inhibitors of angiotensin I converting enzyme.
Inventor(s): Coquerel; Gerard (Boos, FR), Lefebvre; Loic (Mont Saint Aignan, FR), Souvie; Jean-Claude (Pau, FR), Authouart; Pascale (Les Trois Pierres, FR)
Assignee: Les Laboratoires Servier (Suresnes Cedex, FR)
Application Number:12/224,369
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,846,961
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;

Drugs Protected by US Patent 7,846,961

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Adhera PRESTALIA amlodipine besylate; perindopril arginine TABLET;ORAL 205003-001 Jan 21, 2015 RX Yes No   Start Trial   Start Trial Y Y TREATMENT OF HYPERTENSION   Start Trial
Adhera PRESTALIA amlodipine besylate; perindopril arginine TABLET;ORAL 205003-002 Jan 21, 2015 RX Yes No   Start Trial   Start Trial Y Y TREATMENT OF HYPERTENSION   Start Trial
Adhera PRESTALIA amlodipine besylate; perindopril arginine TABLET;ORAL 205003-003 Jan 21, 2015 RX Yes Yes   Start Trial   Start Trial Y Y TREATMENT OF HYPERTENSION   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,846,961

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France06 01748Feb 28, 2006
PCT Information
PCT FiledFebruary 26, 2007PCT Application Number:PCT/FR2007/000335
PCT Publication Date:September 07, 2007PCT Publication Number: WO2007/099217

International Family Members for US Patent 7,846,961

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2007220435   Start Trial
Brazil PI0708278   Start Trial
Canada 2644467   Start Trial
China 101389603   Start Trial
Cyprus 1117753   Start Trial
Denmark 1989182   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Dow
Medtronic
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.